• Atea Pharmaceuticals disclosed Phase 1 data at EASL Congress 2026, with results already presented in conference posters.
• Studies indicated its bemnifosbuvir–ruzasvir hepatitis C regimen can be used with common medicines without meaningful interaction concerns.
• Findings supported co-administration with acid-reducing therapy and a widely used cholesterol drug without dose changes, reducing a key barrier to use.
• Separate preclinical results presented at EASL supported AT-587 as a potential hepatitis E treatment, with the company targeting a mid-year first-in-human study.
• The updates position the hepatitis C regimen for broader real-world use ahead of upcoming Phase 3 topline readouts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270700PRIMZONEFULLFEED9726792) on May 27, 2026, and is solely responsible for the information contained therein.